BIO lawyers up
Executive Summary
The Biotechnology Industry Organization appoints Sandra Dennis to the newly created position of Deputy General Counsel for Healthcare Regulatory Affairs. The addition of Dennis serves to "enhance BIO's advocacy for a regulatory environment that allows biotechnology industry to bring ... technologies to market," BIO President Jim Greenwood says in a Jan. 9 release. The trade association is bolstering its regulatory affairs department at a time many anticipate increased Congressional interest in the establishment of a regulatory framework for approval of generic biologics (1"The Pink Sheet" Nov. 13, 2006, p. 3). Dennis comes to BIO from Morgan, Lewis & Bockius' FDA/Healthcare Regulation practice group, where she focused on regulatory, legislative, policy and corporate issues...
You may also be interested in...
Democratic Capitol Hill Will Create Challenges For Brand Industry
The sweep of both houses of Congress in the midterm elections will allow the Democrats the opportunity to push their agenda through must-pass legislation such as the reauthorization of the Prescription Drug User Fee Act
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.